Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England

Hannah Christensen*, Caroline L. Trotter

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

16 Citations (Scopus)
260 Downloads (Pure)

Abstract

We assessed the cost-effectiveness of offering catch-up vaccination with Bexsero against meningococcal disease to children too old to receive the vaccine under the recently introduced infant programme. Offering catch-up vaccination to increasingly older children is less economically attractive because of declining disease burden. We estimate catch-up vaccination of 1 year old children could be cost-effective, incremental on the infant programme with a vaccine price of ≤£8 per dose. Extending vaccination to 2 year olds could only be cost-effective (incremental on infant and 1 year old catch-up) with a vaccine price of ≤£3 per dose and was not cost-effective in sensitivity analyses with more conservative vaccine assumptions. Extending catch-up further to 3-4 year olds was not cost-effective. Employing the current criteria for assessing vaccines, our models suggest that even with low vaccine prices only catch-up vaccination in 1 year old children could be cost-effective, when considered incrementally on the infant programme.
Original languageEnglish
Pages (from-to)208-211
Number of pages4
JournalVaccine
Volume35
Issue number2
Early online date5 Dec 2016
DOIs
Publication statusPublished - 5 Jan 2017

Keywords

  • Catch-up
  • Cost-effectiveness
  • Group B
  • Meningococcal disease
  • Vaccination

Fingerprint Dive into the research topics of 'Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England'. Together they form a unique fingerprint.

Cite this